The limitations of current therapies for multiple sclerosis (MS) have led to the development of several new oral drugs that target different parts of the MS disease process.
Most of these oral medications in development are based on existing drugs with a history of use in the treatment of other conditions, such as autoimmune diseases and certain cancers.
Oral therapies for multiple sclerosis oral therapies currently in development include :
- Fingolimod (FTY720)
- BG00012 (BG-12 or oral fumarate)
Warning: This section shares scientific information on investigational products that have been developed to date. These products have not yet been approved by any regulatory authority for the treatment of multiple sclerosis, and have not yet been proven to be either safe or effective in this indication.
- Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007;61: 1922–30.